Breast Cancer > Abemaciclib

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

Recruiting in Palo Alto (17 mi)

Overseen By Sara Tolaney, MD, MPH

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Dana-Farber Cancer Institute

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Approved in 2 jurisdictions

Trial Summary

What is the purpose of this trial?

This research study is studying a drug called Abemaciclib as a possible treatment for have metastatic triple-negative type of breast cancer.

Eligibility Criteria

Participant Groups

Group I: Abemaciclib Experimental Treatment 1 Intervention

-Abemaciclib will be administered orally, twice daily on days 1 to 28

Abemaciclib is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Verzenio for:

• Hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer
• HR+, HER2- node-positive early breast cancer

🇪🇺 Approved in European Union as Verzenio for:

• HR+, HER2- advanced or metastatic breast cancer
• HR+, HER2- node-positive early breast cancer

Find A Clinic Near You

Research locations nearby Select from list below to view details:

Dana-Farber Cancer Institute Boston, MA

Who is running the clinical trial?

Dana-Farber Cancer Institute Lead Sponsor

Eli Lilly and Company Industry Sponsor

References